Efficacy and safety evaluation of ciclesonide in mild-tomoderate persistent asthma previously treated with inhaled corticosteroids

Allergy and Asthma Proceedings

Volumn 30, Issue 3, 2009, Pages 293-303

  Meltzer, Eli O ^a   Korenblat, Phillip E ^b   Weinstein, Steven F ^c   Noonan, Michael ^d   Karafilidis, John ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Clinical Research Center   (United States)

^c Allergy and Asthma Specialists Medical Group   (United States)

^d Allergy Associates Research Center   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Asthma; Ciclesonide; Controller medication; Inhaled corticosteroids; Maintenance therapy; Mild to moderate asthma; Pulmonary function; Randomized controlled trial; Rescue medication; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; SALBUTAMOL; SALMETEROL; TRIAMCINOLONE ACETONIDE; ANTIALLERGIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PREGNANE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM; SINUSITIS; SORE THROAT; THRUSH; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ALLERGIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREGNENEDIONES; TREATMENT OUTCOME;

EID: 68249151172     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3241     Document Type: Article

References (36)

1. Skoner JD, Schaffner TJ, Schad CA, et al. Addressing steroid phobia: Improving the risk-benefit ratio with new agents. Allergy Asthma Proc 29:358-364, 2008.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2008. Available online at www.ginasthma.org; last accessed January 2009.
3. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Available online at www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf. 2007; last accessed October 2007.
4. Booth H, Richmond I, Ward C, et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 152:45-52, 1995.
5. Gibson PG, Saltos N, and Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: A randomized controlled trial. Am J Respir Crit Care Med 163:32-36, 2001.
6. Umland SP, Schleimer RP, and Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 15:35-50, 2002.
7. Banov C, Howland WC, III, Lumry WR, et al. Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma. Allergy Asthma Proc 24:129-136, 2003.
8. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-S53, 1998.
9. Karpel JP, Busse WW, Noonan MJ, et al. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 39:1977-1983, 2005.
10. Nathan RA, Kanter L, and Ostrom NK. Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma. Allergy Asthma Proc 29:521-527, 2008.
11. Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: A nonrandomized study in healthy volunteers. J Aerosol Med 19:117-126, 2006.
12. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 309:249-258, 2004.
13. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 73:1657-1664, 2007.
14. Nave R, Fisher R, and Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 27:197-207, 2006.
15. Bender BG, and Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 4:191-195, 2004.
16. Joshi AV, Madhavan SS, Ambegaonkar A, et al. Association of medication adherence with workplace productivity and health-related quality of life in patients with asthma. J Asthma 43:521-526, 2006.
17. Bauman LJ, Wright E, Leickly FE, et al. Relationship of adherence to pediatric asthma morbidity among inner-city children. Pediatrics 110:e6, 2002.
18. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care 50:1346-1356, 2005.
19. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 60:330-337, 2005.
20. Meltzer EO, and Derendorf H. The systemic safety of inhaled corticosteroid therapy: A focus on ciclesonide. Ann Allergy Asthma Immunol 97:149-157, 2006.
21. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12:201-209, 2005.
22. Zitt MJ. Properties of the ideal corticosteroid therapy. Allergy Asthma Proc 26:173-182, 2005.
23. Berger WE. Ciclesonide: A closer look at its systemic and oropharyngeal safety profile. Curr Drug Saf 1:265-270, 2006.
24. Hansel TT, Benezet O, Kafe H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 28:906-920, 2006.
25. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99:1275-1285, 2005.
26. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94:465-472, 2005.
27. Zitt MJ. Advances in inhaled corticosteroid pharmacology. Allergy Asthma Proc 28:114-124, 2007.
28. Craig T. The safety profile of ciclesonide in the treatment of persistent asthma. Allergy Asthma Proc 30:315-324, 2009.
29. Rits IA. Declaration of Helsinki. Recommendations guidings doctors in clinical research. World Med J 11:281, 1964.
30. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 152:1107-1136, 1995.
31. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 116:1206-1212, 2005.
32. Engelstaetter R, Banerji D, Steinijans V, et al. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: Results from a pooled analysis. Am J Respir Crit Care Med 169:A72, 2004 (Abs 37).
33. Skoner DP, Maspero J, and Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 121:e1-e14, 2008.
34. Nave R, Bethke TD, van Marle SP, et al. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43:479-486, 2004.
35. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43:365-378, 2003.
36. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45:146-152, 2005.